Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jessica Merrill

New York, NY
Jessica Merrill is a Bureau Editor for US Commercial Content for Informa’s pharmaceutical news publications, including “The Pink Sheet” and SCRIP. She has been covering the pharmaceutical industry as a journalist for more than 10 years, spanning the spectrum from R&D to regulatory to commercial. She was previously a reporter and editor for “The Pink Sheet” and “Pink Sheet” DAILY, specializing in business and commercial news, focusing largely on big pharma, M&A and business development, and the commercial landscape, including drug launches and market access. Before embarking on a career in healthcare journalism, she covered business news for the cosmetics industry and worked as a newspaper reporter.

Latest From Jessica Merrill

Roche Boosted By COVID-19 Antibody Revenues As Pandemic Recovery Progresses

Ronapreve and Actemra for COVID-19 indications padded the top-line. Roche raised its financial outlook for the year to mid-single digit growth.

Sales & Earnings Coronavirus COVID-19

J&J Expects A Commercial COVID-19 Vaccine Market By Late 2022/2023

The company is currently providing its COVID-19 vaccine on a not-for-profit basis but expects that will change as the pandemic phase of the crisis abates.

Sales & Earnings Coronavirus COVID-19

Q3 Headwinds For Pharma Could Dampen A Continued Rally

COVID-19 disruptions, less favorable currency and the shadow of drug price reform could mean more headwinds for pharma during this S&E period after a strong Q2.

Sales & Earnings Business Strategies

Under The Shadow Of Drug Price Reform, US Tax Policies Still Challenge Pharma

Congress is considering legislation that would reverse some of the Trump administration's friendly corporate tax policies, presenting another challenge to the biopharmaceutical industry.

Politics Sales & Earnings

Under The Shadow Of Drug Price Reform, US Tax Policies Still Challenge Pharma

Congress is considering legislation that would reverse some of the Trump administration's friendly corporate tax policies, presenting another challenge to the biopharmaceutical industry.

Politics Policy

J&J's Longtime R&D Head Stoffels To Retire, Raising The Leadership Transition Stakes

Chief scientific officer Paul Stoffels will retire at the end of the year at the same time CEO Alex Gorsky will hand over the top leadership role to Joaquin Duato; no successor has been named.

Leadership Business Strategies
See All
UsernamePublicRestriction

Register